Apatinib (rivoceranib)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | China, 17 Oct 2014, gastric cancer; later liver cancer. Not approved in US, EU or UK | Level 2 facts table: https://drugs.dxy.cn/drug/0JhFqeRKboisKq8Gf6JQVA== ; PMID 32266817 (3 Nov 2026). entries.json notes NMPA register not opened |
| Mechanism | Tablet blocking VEGFR2, the receptor for a blood vessel growth signal | doi:10.1634/theoncologist.2018-0542 abstract (4 Nov 2026) |
| Use in osteosarcoma | Relapse, in China; Chinese paediatric guideline describes it | CSCO guideline and 2026 Chinese paediatric guideline, via /workspace/osteo-videos/level2/treatment_by_country.md (accessed 31 Oct 2026) |
| Combined with | Alone; with camrelizumab (APFAO phase 2, 43 patients: 6-month PFS rate 50.9%, response 20.9%, target of 60% not met); with liposomal irinotecan (NCT07479732) | Xie et al., J Immunother Cancer 2020, doi:10.1136/jitc-2020-000798 (PMID 32376724) (accessed 4 Nov 2026); entries.json (portal export) |
| Results | Single-centre phase 2, Peking University People's Hospital, 16+, 37 analysed: response 43%, 4-month PFS 57%, median PFS 4.5 months, OS 9.9 months; 68% needed dose reduction or interruption; pneumothorax most common severe event | doi:10.1634/theoncologist.2018-0542 (PMID 30559126), 4 Nov 2026 |
| Side effects | Pneumothorax, high blood pressure, hand-foot skin reaction, protein in urine | same |
| Owner | Developed by Advenchen Laboratories (California) as YN968D1; licensed to Jiangsu Hengrui for China (2005), sold as Aitan; rights outside China licensed to LSK BioPharma, now Elevar Therapeutics (HLB subsidiary), as rivoceranib | Elevar, https://elevartx.com/2018/01/02/lskb-announces-official-nonproprietary-naming-of-apatinib-yn968d1-rivoceranib/ (accessed 4 Nov 2026); Hengrui, https://www.hengrui.com/en/media/detail-423.html (accessed 4 Nov 2026) |
| Regulatory | China only (gastric cancer Dec 2014; liver cancer later; with camrelizumab first-line liver cancer Jan 2023). US: rivoceranib with camrelizumab received FDA complete response letters May 2024, Mar 2025 and Jul 2026 (manufacturing, not efficacy); resubmitted 9 Oct 2026, FDA target date 9 Apr 2027. Not approved in EU or UK. Not osteosarcoma | Elevar CRL release https://elevartx.com/2026/07/10/elevar-crl-july-2/ (accessed 4 Nov 2026); https://www.targetedonc.com/view/rivoceranib-plus-camrelizumab-resubmitted-to-fda-in-frontline-hcc (accessed 4 Nov 2026); Hengrui page above |
Hypotheses and open points (not established fact)
- Apatinib response rates may be higher than other TKIs: single-arm, single-centre, not compared.